Eli Lilly (LLY) vs Recursion Pharmaceuticals (RXRX): Contrasting Paths in Healthcare Innovation
Key Takeaways
- Eli Lilly (LLY) is a large, profitable pharmaceutical leader whose revenue rose 56% year over year in its most recent quarter, driven by its GLP-1 (glucagon-like peptide-1) diabetes and obesity medicines.
- Recursion Pharmaceuticals (RXRX) is a clinical-stage "TechBio" company that uses artificial intelligence (AI) for drug discovery but currently has no approved products and is operating at a net loss.
- The two companies sit at opposite ends of the risk spectrum: LLY offers scale and earnings growth, while RXRX represents a higher-risk, earlier-stage AI platform story.
- RXRX shares have declined substantially year to date, whereas LLY has traded near record highs, supported by strong product demand and raised full-year guidance.
- This stock comparison is most relevant to investors weighing proven commercial momentum against speculative long-term AI-driven upside.
Bringing Two Distinct Healthcare Models Together
Comparing LLY and RXRX highlights two very different paths in medicine. Eli Lilly is a long-established pharmaceutical company capitalizing on strong demand for weight-loss and diabetes treatments, while Recursion Pharmaceuticals is a clinical-stage biotech firm focused on using AI to speed up drug discovery. Both are in healthcare, but their business models, financial positions, and risk levels differ markedly. This kind of comparison helps investors decide between a large-cap name with clear earnings visibility and an earlier-stage player whose prospects depend on pipeline progress and platform results. I also checked recent patterns using Tickeron’s AI Pattern Search Engine to see how the two have moved relative to peers.
Eli Lilly's Commercial Momentum
LLY, or Eli Lilly and Company, is a diversified pharmaceutical company whose cardiometabolic franchise, led by Mounjaro and Zepbound, drives most of its growth. In the latest quarter, revenue reached about $19.8 billion, up 56% from a year earlier, and adjusted earnings per share exceeded analyst expectations. Mounjaro sales increased 125% and Zepbound sales rose 80%, together making up the bulk of total revenue. The stock has held near all-time highs, lifting the company’s market value close to the trillion-dollar level. Recent developments include the launch of Foundayo, an oral GLP-1 pill for obesity, and positive late-stage data for retatrutide. Management raised full-year guidance. Pricing pressure and competition from Novo Nordisk remain factors to monitor, but demand across the portfolio has been the main positive driver. From what I see, the earnings visibility here stands out clearly.
Recursion Pharmaceuticals' AI Platform Focus
RXRX, or Recursion Pharmaceuticals, is a clinical-stage TechBio company that applies automated biology, chemistry, and AI through its Recursion OS platform to discover new medicines. Unlike Lilly, Recursion has no approved products and earns revenue mainly from collaboration and grant agreements with partners including Roche, Sanofi, Bayer, and Merck KGaA. Recent results showed revenue falling sharply year over year to less than $8 million as certain milestones wrapped up, alongside a net loss of about $131 million. The stock is down more than 20% year to date. Progress on REC-4881 for familial adenomatous polyposis and several AI-derived oncology candidates offers potential catalysts, but value still hinges on clinical data and partnership outcomes. Cash runway extends into early 2028. I reviewed the broader sector context with Tickeron’s AI Screener to place RXRX alongside similar platform companies.
Head-to-Head Differences in Scale and Risk
The main distinction lies in financial maturity. LLY generates tens of billions in annual revenue with growing earnings, while RXRX remains pre-revenue on product sales and reports ongoing net losses supported by partnerships and cash reserves. Growth sources also differ: LLY benefits from commercial blockbusters and a late-stage pipeline, whereas RXRX depends on turning its AI platform into clinical and regulatory successes. Both operate in healthcare, yet LLY focuses on cardiometabolic disease with added exposure to immunology, oncology, and neuroscience, while RXRX covers oncology, rare disease, and neuroscience at an earlier stage. Risk profiles reflect this: LLY contends with pricing, competition, and patent issues; RXRX faces clinical, dilution, and milestone-revenue risks. Market sentiment has favored LLY’s stability, leaving RXRX at a discount to its longer-term narrative—a clear trade-off between established strength and higher-upside optionality.
AI-Driven Perspective on the Pair
Looking at trend consistency, earnings visibility, and positioning, the AI analysis points toward greater near-term conviction in LLY. Sustained upward movement, positive earnings momentum, and raised guidance align with the signals that trend and momentum models typically favor. RXRX shows a weaker trend and negative year-to-date performance, even though its AI-platform story carries higher potential on future milestones. This does not eliminate RXRX as an idea, but it suggests clearer evidence of trend improvement and fundamental progress would be needed for comparable weight in a systematic view.
Exploring Automated Trading Strategies
When assessing names like these, I sometimes review Tickeron’s Trending AI Robots to see how automated strategies are currently positioned across similar healthcare tickers. The section highlights a curated selection of bots based on measurable factors such as trade frequency, drawdown, and win rate, which can offer a data-driven complement to manual research. It is one way to evaluate how systematic approaches might handle the relative strength or volatility between established growth names and earlier-stage platform companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
LLY sees MACD Histogram crosses below signal line
LLY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 33 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 73%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In 53 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
LLY moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LLY crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for LLY entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LLY's RSI Oscillator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 263 of 376 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.153) is normal, around the industry mean (19.199). P/E Ratio (39.771) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). LLY has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.025). LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement